KARDIGAN INC
KARDNASDAQTrading Snapshot
- Day Range
- $14.07 β $14.94
- 52-Week Range
- $12.23 β $27.00
- Volume (shares)
- 446,299
- Avg Volume (shares)
- β
- Shares Outstanding
- 89.3M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -6.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.84
- Dividend Yield
- 0.00%
KARDIGAN INC
KARDFinancial history unavailable.
StockOtter Β· stockotter.spaceAbout KARDIGAN INC
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its βCardiac Intelligenceβ platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates
Here Are Thursdayβs Top Wall Street Analyst Research Calls: Alphabet, Boston Scientific, eBay, Fervo Energy, Fortinet, Hilton Worldwide Holdings, Lennox International, Palantir Technologies, and More
Pre-Market Stock Futures: Futures are trading lower after a solid day for the stock market, as the interest-rate scenario played out as we (and most across Wall Street) predicted, with the Federal Reserve holding rates s
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committ
Kardigan, Inc. (NASDAQ:KARD) Stock Has Consensus Price Target of $42.25 According to Analysts
Shares of Kardigan, Inc. (NASDAQ: KARD - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst h
Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification
Kardigan targets genetic DCM, moderate CAVS, and post-hospitalization ASH with differentiated, biology-driven clinical programs. KARD holds $660.7M in liquid assets, providing roughly 2β3 years of runway to achieve key c
Kardigan to Present at Two September Investor Conferences
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan will participate in two upcoming investor conferences: 2026 Cantor Global Healthcare Conference and Baird's 2026 Global Healthc
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
KardiganΓ’ΒΒ’, Inc. (Nasdaq: KARD) (Γ’ΒΒKardiganΓ’ΒΒ or Γ’ΒΒthe CompanyΓ’ΒΒ), a clinical-stage precision therapeutics company developing medicines that target the roo